617 related articles for article (PubMed ID: 16280328)
21. Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo.
Franco GC; Kajiya M; Nakanishi T; Ohta K; Rosalen PL; Groppo FC; Ernst CW; Boyesen JL; Bartlett JD; Stashenko P; Taubman MA; Kawai T
Exp Cell Res; 2011 Jun; 317(10):1454-64. PubMed ID: 21420951
[TBL] [Abstract][Full Text] [Related]
22. Effects of the phytoestrogen coumestrol on RANK-ligand-induced differentiation of osteoclasts.
Kanno S; Hirano S; Kayama F
Toxicology; 2004 Oct; 203(1-3):211-20. PubMed ID: 15363596
[TBL] [Abstract][Full Text] [Related]
23. [The effect of ferric ion on the differentiation of osteoclast and bone resorption].
Jia P; He YF; Gao C; Du HB; Hu ZY; Feng XQ; Li BY; Zhang ZL; Xu YJ; Lin H
Zhonghua Yi Xue Za Zhi; 2012 Aug; 92(31):2214-8. PubMed ID: 23158430
[TBL] [Abstract][Full Text] [Related]
24. The paired-box homeodomain transcription factor Pax6 binds to the upstream region of the TRAP gene promoter and suppresses receptor activator of NF-κB ligand (RANKL)-induced osteoclast differentiation.
Kogawa M; Hisatake K; Atkins GJ; Findlay DM; Enoki Y; Sato T; Gray PC; Kanesaki-Yatsuka Y; Anderson PH; Wada S; Kato N; Fukuda A; Katayama S; Tsujimoto M; Yoda T; Suda T; Okazaki Y; Matsumoto M
J Biol Chem; 2013 Oct; 288(43):31299-312. PubMed ID: 23990468
[TBL] [Abstract][Full Text] [Related]
25. Constant hypoxia inhibits osteoclast differentiation and bone resorption by regulating phosphorylation of JNK and IκBα.
Ma Z; Yu R; Zhao J; Sun L; Jian L; Li C; Liu X
Inflamm Res; 2019 Feb; 68(2):157-166. PubMed ID: 30604211
[TBL] [Abstract][Full Text] [Related]
26. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
27. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro.
Spencer GJ; Utting JC; Etheridge SL; Arnett TR; Genever PG
J Cell Sci; 2006 Apr; 119(Pt 7):1283-96. PubMed ID: 16522681
[TBL] [Abstract][Full Text] [Related]
28. Effects of continuous calcitonin treatment on osteoclast-like cell development and calcitonin receptor expression in mouse bone marrow cultures.
Ikegame M; Rakopoulos M; Martin TJ; Moseley JM; Findlay DM
J Bone Miner Res; 1996 Apr; 11(4):456-65. PubMed ID: 8992876
[TBL] [Abstract][Full Text] [Related]
29. Receptor activator of nuclear factor-kappaB ligand-induced nuclear factor of activated T cells (C1) autoregulates its own expression in osteoclasts and mediates the up-regulation of tartrate-resistant acid phosphatase.
Fretz JA; Shevde NK; Singh S; Darnay BG; Pike JW
Mol Endocrinol; 2008 Mar; 22(3):737-50. PubMed ID: 18063694
[TBL] [Abstract][Full Text] [Related]
30. Novel antiosteoclastogenic activity of phloretin antagonizing RANKL-induced osteoclast differentiation of murine macrophages.
Kim JL; Kang MK; Gong JH; Park SH; Han SY; Kang YH
Mol Nutr Food Res; 2012 Aug; 56(8):1223-33. PubMed ID: 22700286
[TBL] [Abstract][Full Text] [Related]
31. IL-4 inhibits bone-resorbing activity of mature osteoclasts by affecting NF-kappa B and Ca2+ signaling.
Mangashetti LS; Khapli SM; Wani MR
J Immunol; 2005 Jul; 175(2):917-25. PubMed ID: 16002690
[TBL] [Abstract][Full Text] [Related]
32. Activation of liver X receptor (LXR) inhibits receptor activator of nuclear factor κB ligand (RANKL)-induced osteoclast differentiation in an LXRβ-dependent mechanism.
Remen KM; Henning P; Lerner UH; Gustafsson JÅ; Andersson G
J Biol Chem; 2011 Sep; 286(38):33084-94. PubMed ID: 21784849
[TBL] [Abstract][Full Text] [Related]
33. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
34. Coenzyme q10 regulates osteoclast and osteoblast differentiation.
Moon HJ; Ko WK; Jung MS; Kim JH; Lee WJ; Park KS; Heo JK; Bang JB; Kwon IK
J Food Sci; 2013 May; 78(5):H785-891. PubMed ID: 23582186
[TBL] [Abstract][Full Text] [Related]
35. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
36. Osteoclast formation elicited by interleukin-33 stimulation is dependent upon the type of osteoclast progenitor.
Eeles DG; Hodge JM; Singh PP; Schuijers JA; Grills BL; Gillespie MT; Myers DE; Quinn JM
Mol Cell Endocrinol; 2015 Jan; 399():259-66. PubMed ID: 25458701
[TBL] [Abstract][Full Text] [Related]
37. Differential expression of chemokines, chemokine receptors and proteinases by foreign body giant cells (FBGCs) and osteoclasts.
Khan UA; Hashimi SM; Khan S; Quan J; Bakr MM; Forwood MR; Morrison NM
J Cell Biochem; 2014 Jul; 115(7):1290-8. PubMed ID: 24500983
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of osteoclast differentiation and bone resorption by N-methylpyrrolidone.
Ghayor C; Correro RM; Lange K; Karfeld-Sulzer LS; Grätz KW; Weber FE
J Biol Chem; 2011 Jul; 286(27):24458-66. PubMed ID: 21613210
[TBL] [Abstract][Full Text] [Related]
39. Serum calcium-decreasing factor, caldecrin, inhibits osteoclast differentiation by suppression of NFATc1 activity.
Hasegawa H; Kido S; Tomomura M; Fujimoto K; Ohi M; Kiyomura M; Kanegae H; Inaba A; Sakagami H; Tomomura A
J Biol Chem; 2010 Aug; 285(33):25448-57. PubMed ID: 20547767
[TBL] [Abstract][Full Text] [Related]
40. Expression of the calcitonin receptor in bone marrow cell cultures and in bone: a specific marker of the differentiated osteoclast that is regulated by calcitonin.
Lee SK; Goldring SR; Lorenzo JA
Endocrinology; 1995 Oct; 136(10):4572-81. PubMed ID: 7664679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
